Literature DB >> 24414193

The role of epithelial plasticity in prostate cancer dissemination and treatment resistance.

Rhonda L Bitting1, Daneen Schaeffer, Jason A Somarelli, Mariano A Garcia-Blanco, Andrew J Armstrong.   

Abstract

Nearly 30,000 men die annually in the USA of prostate cancer, nearly uniformly from metastatic dissemination. Despite recent advances in hormonal, immunologic, bone-targeted, and cytotoxic chemotherapies, treatment resistance and further dissemination are inevitable in men with metastatic disease. Emerging data suggests that the phenomenon of epithelial plasticity, encompassing both reversible mesenchymal transitions and acquisition of stemness traits, may underlie this lethal biology of dissemination and treatment resistance. Understanding the molecular underpinnings of this cellular plasticity from preclinical models of prostate cancer and from biomarker studies of human metastatic prostate cancer has provided clues to novel therapeutic approaches that may delay or prevent metastatic disease and lethality over time. This review will discuss the preclinical and clinical evidence for epithelial plasticity in this rapidly changing field and relate this to clinical phenotype and resistance in prostate cancer while suggesting novel therapeutic approaches.

Entities:  

Mesh：

Year:  2014        PMID： 24414193      PMCID： PMC4230790          DOI： 10.1007/s10555-013-9483-z

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN： 0167-7659            Impact factor:   9.264


  263 in total

1.  Snail-mediated regulation of reactive oxygen species in ARCaP human prostate cancer cells.

Authors:  Petrina Barnett; Rebecca S Arnold; Roman Mezencev; Leland W K Chung; Majd Zayzafoon; Valerie Odero-Marah
Journal:  Biochem Biophys Res Commun       Date:  2010-11-17       Impact factor: 3.575

Review 2.  Active cell death in hormone-dependent tissues.

Authors:  M P Tenniswood; R S Guenette; J Lakins; M Mooibroek; P Wong; J E Welsh
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

Review 3.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

Authors:  Héctor Peinado; David Olmeda; Amparo Cano
Journal:  Nat Rev Cancer       Date:  2007-05-17       Impact factor: 60.716

4.  The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.

Authors:  Andrew J Armstrong; Ian F Tannock; Ronald de Wit; Daniel J George; Mario Eisenberger; Susan Halabi
Journal:  Eur J Cancer       Date:  2009-12-11       Impact factor: 9.162

5.  Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer.

Authors:  Giridhar Mudduluru; Peter Vajkoczy; Heike Allgayer
Journal:  Mol Cancer Res       Date:  2010-02-09       Impact factor: 5.852

6.  Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness.

Authors:  Elisa Giannoni; Francesca Bianchini; Lorenzo Masieri; Sergio Serni; Eugenio Torre; Lido Calorini; Paola Chiarugi
Journal:  Cancer Res       Date:  2010-08-10       Impact factor: 12.701

7.  Evidence of epithelial to mesenchymal transition associated with increased tumorigenic potential in an immortalized normal prostate epithelial cell line.

Authors:  Calin O Marian; Lin Yang; Ying S Zou; Crystal Gore; Rey-Chen Pong; Jerry W Shay; Wareef Kabbani; Jer-Tsong Hsieh; Ganesh V Raj
Journal:  Prostate       Date:  2010-10-13       Impact factor: 4.104

8.  TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.

Authors:  Zhan Yao; Silvia Fenoglio; Ding Cheng Gao; Matthew Camiolo; Brendon Stiles; Trine Lindsted; Michaela Schlederer; Chris Johns; Nasser Altorki; Vivek Mittal; Lukas Kenner; Raffaella Sordella
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

9.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

10.  miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells.

Authors:  Dejuan Kong; Yiwei Li; Zhiwei Wang; Sanjeev Banerjee; Aamir Ahmad; Hyeong-Reh Choi Kim; Fazlul H Sarkar
Journal:  Stem Cells       Date:  2009-08       Impact factor: 6.277
View more
  34 in total

Review 1.  Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.

Authors:  Kathryn E Ware; Mariano A Garcia-Blanco; Andrew J Armstrong; Scott M Dehm
Journal:  Endocr Relat Cancer       Date:  2014-05-23       Impact factor: 5.678

2.  A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.

Authors:  L A Selth; R Das; S L Townley; I Coutinho; A R Hanson; M M Centenera; N Stylianou; K Sweeney; C Soekmadji; L Jovanovic; C C Nelson; A Zoubeidi; L M Butler; G J Goodall; B G Hollier; P A Gregory; W D Tilley
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

Review 3.  Are androgen receptor variants a substitute for the full-length receptor?

Authors:  Ji Lu; Travis Van der Steen; Donald J Tindall
Journal:  Nat Rev Urol       Date:  2015-02-10       Impact factor: 14.432

4.  Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells.

Authors:  Kathryn E Ware; Shivee Gilja; Shenghan Xu; Samantha Shetler; Mohit K Jolly; Xueyang Wang; Suzanne Bartholf Dewitt; Alexander J Hish; Sarah Jordan; William Eward; Herbert Levine; Andrew J Armstrong; Jason A Somarelli
Journal:  J Vis Exp       Date:  2017-04-07       Impact factor: 1.355

5.  Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2.

Authors:  Jason A Somarelli; Samantha Shetler; Mohit K Jolly; Xueyang Wang; Suzanne Bartholf Dewitt; Alexander J Hish; Shivee Gilja; William C Eward; Kathryn E Ware; Herbert Levine; Andrew J Armstrong; Mariano A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  2016-09-12       Impact factor: 4.272

Review 6.  Using circulating tumor cells to inform on prostate cancer biology and clinical utility.

Authors:  Jing Li; Simon G Gregory; Mariano A Garcia-Blanco; Andrew J Armstrong
Journal:  Crit Rev Clin Lab Sci       Date:  2015-06-16       Impact factor: 6.250

Review 7.  Biphasic malignant tumours of the abdominal cavity.

Authors:  L Max Almond; Adrian T Warfield; Anant Desai; David Gourevitch; Samuel J Ford
Journal:  Int J Clin Oncol       Date:  2017-06-27       Impact factor: 3.402

Review 8.  Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.

Authors:  E S Antonarakis; A J Armstrong; S M Dehm; J Luo
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-17       Impact factor: 5.554

Review 9.  Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.

Authors:  Tian Zhang; Andrew J Armstrong
Journal:  Curr Oncol Rep       Date:  2016-01       Impact factor: 5.075

10.  Juglone suppresses epithelial-mesenchymal transition in prostate cancer cells via the protein kinase B/glycogen synthase kinase-3β/Snail signaling pathway.

Authors:  Fang Fang; Shuang Chen; Jing Ma; Jiabo Cui; Qiang Li; Guixian Meng; Liguo Wang
Journal:  Oncol Lett       Date:  2018-06-04       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.